{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:49:05Z","timestamp":1785268145254,"version":"3.55.0"},"reference-count":57,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T00:00:00Z","timestamp":1689292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Recent clinical findings reported the reduced mortality associated with treatment guided by sputum-based molecular test with urine-based lipoarabinomannan (LAM) assay for tuberculosis (TB) disease in HIV-infected individuals. We aimed to evaluate the cost-effectiveness of sputum-based Xpert tests with and without urine-based LAM assays among HIV-infected individuals with signs and symptoms of TB disease (TBD) from the perspective of South African healthcare providers.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A one-year decision-analytic model was constructed to simulate TB-related outcomes of 7 strategies: Sputum smear microscope (SSM), Xpert, Xpert Ultra, Xpert with AlereLAM, Xpert Ultra with AlereLAM, Xpert with FujiLAM, and Xpert Ultra with FujiLAM, in a hypothetical cohort of adult HIV-infected individuals with signs and symptoms of TB. The model outcomes were TB-related direct medical cost, mortality, early treatment, disability-adjusted life-years (DALYs) and incremental cost per DALY averted (ICER). The model inputs were retrieved from literature and public data. Base-case analysis and sensitivity analysis were conducted.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>In the base-case analysis, the Xpert Ultra with FujiLAM strategy showed the highest incidence of early treatment (267.7 per 1000 tested) and lowest mortality (29.0 per 1000 tested), with ICER = 676.9 USD\/DALY averted. Probabilistic sensitivity analysis of 10,000 Monte Carlo simulations showed the cost-effective probability of Xpert Ultra with FujiLAM was the highest of all 7 strategies at the willingness-to-pay (WTP) threshold &gt;202USD\/DALY averted.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Standard sputum-based TB diagnostic Xpert Ultra with urine-based FujiLAM for TBD testing in HIV-infected individuals appears to be the preferred cost-effective strategy from the perspective of the health service provider of South Africa.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0288605","type":"journal-article","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T17:38:12Z","timestamp":1689356292000},"page":"e0288605","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Standard diagnostics with and without urine-based lipoarabinomannan testing for tuberculosis disease in HIV-infected patients in a high-burden setting\u2013A cost-effectiveness analysis"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4926-0685","authenticated-orcid":true,"given":"Ginenus","family":"Fekadu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingcheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5763-7403","authenticated-orcid":true,"given":"Joyce H. S.","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,7,14]]},"reference":[{"key":"pone.0288605.ref001","volume-title":"Global Tuberculosis Report 2022","author":"World Health Organization","year":"2022"},{"key":"pone.0288605.ref002","volume-title":"WHO consolidated guidelines on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection:","author":"World Health Organization","year":"2021"},{"issue":"6","key":"pone.0288605.ref003","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1183\/09031936.00217313","article-title":"Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential?","volume":"43","author":"SV Kik","year":"2014","journal-title":"European Respiratory Journal"},{"issue":"8","key":"pone.0288605.ref004","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1586\/14737159.2013.850034","article-title":"Robust, reliable and resilient: designing molecular tuberculosis tests for microscopy centers in developing countries.","volume":"13","author":"CM Denkinger","year":"2013","journal-title":"Expert Rev Mol Diagn"},{"issue":"2","key":"pone.0288605.ref005","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/bbrj.bbrj_54_19","article-title":"Sputum smear microscopy in tuberculosis: It is still relevant in the era of molecular diagnosis when seen from the public health perspective","volume":"3","author":"PK Das","year":"2019","journal-title":"Biomedical and Biotechnology Research Journal"},{"issue":"8","key":"pone.0288605.ref006","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S2214-109X(15)00100-X","article-title":"Xpert MTB\/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB\/RIF","volume":"3","author":"GJ Churchyard","year":"2015","journal-title":"The Lancet Global Health"},{"key":"pone.0288605.ref007","volume-title":"WHO operational handbook on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection","author":"World Health Organization","year":"2021"},{"issue":"2","key":"pone.0288605.ref008","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.rppnen.2017.12.002","article-title":"Point of care diagnostics for tuberculosis","volume":"24","author":"AL Garc\u00eda-Basteiro","year":"2018","journal-title":"Pulmonology"},{"issue":"2","key":"pone.0288605.ref009","first-page":"CD009593","article-title":"Xpert Ultra versus Xpert MTB\/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis.","author":"JS Zifodya","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"639","key":"pone.0288605.ref010","doi-asserted-by":"crossref","first-page":"eabj4124","DOI":"10.1126\/scitranslmed.abj4124","article-title":"Point-of-care diagnostic tests for tuberculosis disease","volume":"14","author":"JM Hong","year":"2022","journal-title":"Science Translational Medicine"},{"issue":"10024","key":"pone.0288605.ref011","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(15)01092-2","article-title":"Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial","volume":"387","author":"JG Peter","year":"2016","journal-title":"The Lancet"},{"key":"pone.0288605.ref012","article-title":"Lipoarabinomannan as a point-of-care assay for diagnosis of tuberculosis: How far are we to use it?","volume":"839","author":"J Flores","year":"2021","journal-title":"Frontiers in microbiology."},{"issue":"8","key":"pone.0288605.ref013","first-page":"CD014641","article-title":"Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV","author":"RR Nathavitharana","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"pone.0288605.ref014","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1473-3099(19)30001-5","article-title":"Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study","volume":"19","author":"T Broger","year":"2019","journal-title":"The Lancet infectious diseases"},{"issue":"1","key":"pone.0288605.ref015","doi-asserted-by":"crossref","first-page":"ofz530","DOI":"10.1093\/ofid\/ofz530","article-title":"Diagnostic accuracy of a novel and rapid lipoarabinomannan test for diagnosing tuberculosis among people with human immunodeficiency virus","volume":"7","author":"S Bjerrum","year":"2020","journal-title":"Open forum infectious diseases"},{"issue":"5","key":"pone.0288605.ref016","first-page":"667","article-title":"Modeling good research practices\u2014overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20131.","volume":"32","author":"JJ Caro","year":"2012"},{"issue":"1","key":"pone.0288605.ref017","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","article-title":"Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR task force on good research practices\u2014Modeling studies.","volume":"6","author":"MC Weinstein","year":"2003","journal-title":"Value in health."},{"key":"pone.0288605.ref018","volume-title":"WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment","author":"World Health Organization","year":"2022"},{"key":"pone.0288605.ref019","unstructured":"Department of Health-South Africa. South African National TB Guidelines\u2014Adults: National Department of Health; 2017 [cited 2022 December 25]. Available from: https:\/\/www.knowledgehub.org.za\/system\/files\/elibdownloads\/2022-09\/TB%20Adult_2017.pdf."},{"key":"pone.0288605.ref020","unstructured":"Department of Health\u2014South Africa. Interim clinical guidance for the implementation of injectable-free regimens for rifampicin-resistant tuberculosis in adults, adolescents and children; South Africa2018 [cited 2022 December 18]. Available from: https:\/\/www.tbonline.info\/media\/uploads\/documents\/dr_tb_clinical_guidelines_for_rsa_september_2018.pdf."},{"key":"pone.0288605.ref021","volume-title":"WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment\u2014Drug-Resistant Tuberculosis Treatment.","author":"World Health Organization","year":"2020"},{"issue":"6","key":"pone.0288605.ref022","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.21037\/jtd.2017.05.31","article-title":"South African guideline for the management of community-acquired pneumonia in adults.","volume":"9","author":"TH Boyles","year":"2017","journal-title":"J Thorac Dis"},{"issue":"3","key":"pone.0288605.ref023","doi-asserted-by":"crossref","first-page":"e34156","DOI":"10.1371\/journal.pone.0034156","article-title":"Tuberculosis Incidence Rates during 8 Years of Follow-Up of an Antiretroviral Treatment Cohort in South Africa: Comparison with Rates in the Community.","volume":"7","author":"A Gupta","year":"2012","journal-title":"PLoS ONE."},{"key":"#cr-split#-pone.0288605.ref024.1","unstructured":"Department of Health- South Africa. Annual report 2021\/2022 South Africa: National Department of Health, Republic of South Africa"},{"key":"#cr-split#-pone.0288605.ref024.2","unstructured":"2022 [cited 2022 November]. Available from: https:\/\/www.gov.za\/sites\/default\/files\/gcis_document\/202210\/healthannualreport202122.pdf."},{"issue":"1","key":"pone.0288605.ref025","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1471-2458-8-68","article-title":"Sputum microscopy for the diagnosis of HIV-associated pulmonary tuberculosis in Tanzania","volume":"8","author":"M Matee","year":"2008","journal-title":"BMC public health"},{"issue":"5","key":"pone.0288605.ref026","doi-asserted-by":"crossref","first-page":"e1003113","DOI":"10.1371\/journal.pmed.1003113","article-title":"Diagnostic accuracy of a novel tuberculosis point-of-care urine lipoarabinomannan assay for people living with HIV: a meta-analysis of individual in-and outpatient data.","volume":"17","author":"T Broger","year":"2020","journal-title":"PLoS medicine"},{"issue":"1","key":"pone.0288605.ref027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-13-507","article-title":"Meta-analysis to compare the accuracy of GeneXpert, MODS and the WHO 2007 algorithm for diagnosis of smear-negative pulmonary tuberculosis","volume":"13","author":"S Walusimbi","year":"2013","journal-title":"BMC infectious diseases"},{"issue":"1","key":"pone.0288605.ref028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-95331-w","article-title":"Mortality during tuberculosis treatment in South Africa using an 8-year analysis of the national tuberculosis treatment register.","volume":"11","author":"M Osman","year":"2021","journal-title":"Sci Rep."},{"key":"pone.0288605.ref029","doi-asserted-by":"crossref","first-page":"106336","DOI":"10.1016\/j.phrs.2022.106336","article-title":"Bedaquiline and Linezolid improve anti-TB treatment outcome in drug-resistant TB patients with HIV: A systematic review and meta-analysis","author":"Y Wu","year":"2022","journal-title":"Pharmacological Research"},{"issue":"1","key":"pone.0288605.ref030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-021-06745-w","article-title":"Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality\u2014a multicentre prospective cohort study.","volume":"21","author":"C Kraef","year":"2021","journal-title":"BMC infectious diseases"},{"issue":"1","key":"pone.0288605.ref031","doi-asserted-by":"crossref","first-page":"e29775","DOI":"10.1371\/journal.pone.0029775","article-title":"Health Related Quality of Life among Patients with Tuberculosis and HIV in Thailand.","volume":"7","author":"W Kittikraisak","year":"2012","journal-title":"Plos One"},{"issue":"6","key":"pone.0288605.ref032","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00005650-199806000-00002","article-title":"Toward consistency in cost-utility analyses\u2014Using national measures to create condition-specific values.","volume":"36","author":"MR Gold","year":"1998","journal-title":"Medical Care"},{"issue":"10","key":"pone.0288605.ref033","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/tmi.12544","article-title":"Cost per patient of treatment for rifampicin\u2010resistant tuberculosis in a community\u2010based programme in Khayelitsha, South Africa.","volume":"20","author":"H Cox","year":"2015","journal-title":"Tropical Medicine & International Health."},{"issue":"2","key":"pone.0288605.ref034","doi-asserted-by":"crossref","first-page":"216","DOI":"10.5588\/ijtld.14.0565","article-title":"Market assessment of tuberculosis diagnostics in South Africa, 2012\u20132013.","volume":"19","author":"TB Diagnostics Market Analysis Consortium","year":"2015","journal-title":"Int J Tuberc Lung Dis."},{"key":"pone.0288605.ref035","unstructured":"Stop TB Partnership. Global Drug Facility: diagnostics, medical devices and other health products catalog Geneva;2022 [cited 2022 December 15]. Available from: https:\/\/www.stoptb.org\/sites\/default\/files\/gdfdiagnosticsmedicaldevotherhealthproductscatalog_0.pdf."},{"issue":"7","key":"pone.0288605.ref036","doi-asserted-by":"crossref","first-page":"e2077","DOI":"10.1093\/cid\/ciaa1698","article-title":"Cost-effectiveness of a Novel Lipoarabinomannan Test for Tuberculosis in Patients With Human Immunodeficiency Virus","volume":"73","author":"KP Reddy","year":"2021","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"pone.0288605.ref037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-13-352","article-title":"Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drug-resistant tuberculosis in South Africa","volume":"13","author":"M Shah","year":"2013","journal-title":"BMC infectious diseases"},{"issue":"1","key":"pone.0288605.ref038","doi-asserted-by":"crossref","first-page":"e54587","DOI":"10.1371\/journal.pone.0054587","article-title":"What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa?","volume":"8","author":"A Pooran","year":"2013","journal-title":"PloS one."},{"key":"pone.0288605.ref039","unstructured":"Department of Health -South Africa. Contractual price adjustment for HP02-2019AI: Supply and delivery of anti-infective medicines 2020 [cited 2022 December 10]. Available from: https:\/\/www.health.gov.za\/wp-content\/uploads\/2021\/03\/HP02-2019AI-Add-2-15-CPA-Effective-1-April-2020.pdf."},{"issue":"3","key":"pone.0288605.ref040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5588\/pha.12.0003","article-title":"Costs and process of in-patient tuberculosis management at a central academic hospital, Cape Town, South Africa.","volume":"2","author":"J Janson","year":"2012","journal-title":"Public health action."},{"issue":"3","key":"pone.0288605.ref041","first-page":"429","article-title":"Quantifying the burden of disease: the technical basis for disability-adjusted life years","volume":"72","author":"CJ Murray","year":"1994","journal-title":"Bulletin of the World health Organization"},{"key":"pone.0288605.ref042","volume-title":"WHO methods and data sources for global burden of disease estimates 2000\u20132019","author":"World Health Organization","year":"2020"},{"issue":"1","key":"pone.0288605.ref043","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1146\/annurev.publhealth.23.100901.140513","article-title":"HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population Health.","volume":"23","author":"MR Gold","year":"2002","journal-title":"Annual review of public health."},{"key":"pone.0288605.ref044","unstructured":"National Collaborating Centre for Infectious Diseases. Understanding Summary Measures Used to Estimate the Burden of Disease 2015 [cited 2023 May 15]. Available from: https:\/\/nccid.ca\/wp-content\/uploads\/sites\/2\/2015\/03\/GBD_Factsheet_FINAL_E.pdf."},{"key":"pone.0288605.ref045","unstructured":"Young TK. Population health: concepts and methods: Oxford University Press; 2004 [cited 2023 May 15]. Available from: https:\/\/api.pageplace.de\/preview\/DT0400.9780199748037_A24395334\/preview-9780199748037_A24395334.pdf."},{"key":"pone.0288605.ref046","volume-title":"Global Health Observatory data repository. Life tables by country_South Africa.","author":"World Health Organization","year":"2019"},{"issue":"4","key":"pone.0288605.ref047","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1524-4733.2008.00489.x","article-title":"Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report.","volume":"12","author":"M Drummond","year":"2009","journal-title":"Value in health."},{"issue":"8","key":"pone.0288605.ref048","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/j.1524-4733.2009.00605.x","article-title":"The ISPOR good practices for quality improvement of cost\u2010effectiveness research task force report.","volume":"12","author":"WF McGhan","year":"2009","journal-title":"Value in Health."},{"key":"pone.0288605.ref049","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2165\/11314120-000000000-00000","article-title":"Utilities of the EQ-5D: transferable or not?","volume":"27","author":"S Knies","year":"2009","journal-title":"PharmacoEconomics."},{"key":"pone.0288605.ref050","unstructured":"Statistics South Africa. Statistical Release P0141 Consumer Price Index. Pretoria;2022 [cited 2022 December 05]. Available from: https:\/\/www.statssa.gov.za\/publications\/P0141\/P0141September2022.pdf."},{"key":"pone.0288605.ref051","volume-title":"The world health report 2002: reducing risks, promoting healthy life.","author":"World Health Organization","year":"2002"},{"key":"pone.0288605.ref052","unstructured":"World Bank. GDP per capita (current US$)\u2014South Africa 2021 [cited 2022 December 24]. Available from: https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD?locations=ZA."},{"issue":"1","key":"pone.0288605.ref053","doi-asserted-by":"crossref","first-page":"e0227138","DOI":"10.1371\/journal.pone.0227138","article-title":"Cost-effectiveness of diagnostic algorithms including lateral-flow urine lipoarabinomannan for HIV-positive patients with symptoms of tuberculosis","volume":"15","author":"N Yakhelef","year":"2020","journal-title":"PLoS One"},{"issue":"18","key":"pone.0288605.ref054","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1097\/QAD.0000000000000008","article-title":"Cost-effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV-infected individuals in Uganda","volume":"27","author":"M Shah","year":"2013","journal-title":"AIDS"},{"issue":"4","key":"pone.0288605.ref055","doi-asserted-by":"crossref","first-page":"552","DOI":"10.5588\/ijtld.12.0627","article-title":"Cost utility of lateral-flow urine lipoarabinomannan for tuberculosis diagnosis in HIV-infected African adults","volume":"17","author":"D Sun","year":"2013","journal-title":"The International journal of tuberculosis and lung disease"},{"issue":"2","key":"pone.0288605.ref056","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2214-109X(18)30436-4","article-title":"Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study","volume":"7","author":"KP Reddy","year":"2019","journal-title":"The Lancet Global Health"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0288605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T17:39:25Z","timestamp":1689356365000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0288605"}},"subtitle":[],"editor":[{"given":"Dzintars","family":"Gotham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,7,14]]},"references-count":57,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0288605","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,14]]}}}